President Donald Trump said Thursday that brand-name or patented pharmaceuticals will face a 100% tariff beginning Oct. 1 unless the manufacturer is building a U.S. plant. Trump framed the move as a way to pressure companies to expand domestic production and strengthen medicine supply chains.
Drugmakers Race to Expand U.S. Manufacturing
Major pharmaceutical firms have already unveiled plans worth hundreds of billions to build or expand U.S. facilities. Eli Lilly recently announced a $6.5 billion plant in Houston and a $5 billion site in Virginia. Trump clarified on Truth Social that projects counted as “building” if construction has broken ground.
Market Reaction and Industry Concerns
Stocks of large European drugmakers barely moved following the announcement, as many already operate U.S. facilities. Asian pharmaceutical stocks dipped more sharply. The Pharmaceutical Research and Manufacturers of America warned that tariffs could divert funds from research and U.S. investments.
Limited Impact Expected in Near Term
Analysts say the immediate effect will be modest. Many big drugmakers have U.S. production or stockpiles, and a global manufacturing network means the U.S. will still depend on foreign ingredients. Smaller manufacturers without U.S. plants may face higher costs.
Generics Largely Exempt—for Now
Trump’s plan targets only brand-name drugs, leaving generic imports untaxed. Experts caution that future action on generics could worsen shortages. India, a major generic supplier, is expected to avoid impact because of existing U.S. facilities and its focus on low-cost medicines.
Broader Tariff Push
The pharmaceutical tariff coincides with Trump’s new levies on other goods, including a 50% tariff on kitchen cabinets, a 30% tariff on upholstered furniture, and a 25% tariff on heavy trucks made outside the U.S.
For more on Trump’s tariffs, stay informed with Que Onda Magazine.